Brokers Set Expectations for LRMR Q1 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Stock analysts at Lifesci Capital issued their Q1 2026 earnings per share (EPS) estimates for Larimar Therapeutics in a research report issued on Wednesday, April 1st. Lifesci Capital analyst F. Brisebois anticipates that the company will post earnings per share of ($0.66) for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Lifesci Capital also issued estimates for Larimar Therapeutics’ Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.36) EPS and FY2026 earnings at ($2.00) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.30).

Other research analysts have also issued reports about the stock. Wedbush upped their target price on shares of Larimar Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, March 20th. Citigroup lifted their price target on shares of Larimar Therapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Truist Financial upgraded Larimar Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Thursday, January 22nd. Finally, Leerink Partners raised Larimar Therapeutics to a “strong-buy” rating in a report on Monday, January 5th. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $16.50.

Larimar Therapeutics Stock Up 2.4%

Shares of NASDAQ LRMR opened at $4.79 on Thursday. The stock has a market capitalization of $497.59 million, a price-to-earnings ratio of -2.17 and a beta of 1.02. Larimar Therapeutics has a 52 week low of $1.61 and a 52 week high of $6.42. The firm has a 50-day moving average price of $4.20 and a 200 day moving average price of $3.96.

Hedge Funds Weigh In On Larimar Therapeutics

A number of institutional investors have recently made changes to their positions in LRMR. BNP Paribas Financial Markets lifted its position in shares of Larimar Therapeutics by 75.8% in the third quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock valued at $33,000 after acquiring an additional 4,376 shares in the last quarter. B.O.S.S. Retirement Advisors LLC purchased a new stake in Larimar Therapeutics during the 3rd quarter worth about $41,000. Coldstream Capital Management Inc. purchased a new stake in Larimar Therapeutics during the 3rd quarter worth about $57,000. Wealth Enhancement Advisory Services LLC raised its stake in Larimar Therapeutics by 33.9% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 18,248 shares of the company’s stock valued at $59,000 after purchasing an additional 4,619 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Larimar Therapeutics in the 4th quarter valued at about $60,000. 91.92% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director James E. Flynn acquired 5,000,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $25,000,000.00. Following the transaction, the director directly owned 10,622,957 shares of the company’s stock, valued at approximately $53,114,785. This trade represents a 88.92% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.50% of the stock is owned by corporate insiders.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.